Alder Biopharmaceuticals to Present at Jefferies Global Healthcare Conference
BOTHELL, Wash., June 4, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that the company is scheduled to present at the Jefferies Global Healthcare Conference at 11:30 a.m. EDT on Tuesday, June 5. Randall Schatzman, Ph.D., president and chief executive officer, will provide an overview of the company and an update about its clinical programs.
"We look forward to this opportunity to provide an update about Alder as we move forward with clinical investigations of ALD518 in cancer supportive care and ALD403 in migraine," said Schatzman. "Following our recent round of financing, we are prepared to move forward with these and other antibody therapeutics generated by our core technologies."
About Alder Biopharmaceuticals
Alder BioPharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. The company's investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now in clinical trials. ALD518 is Alder's investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Alder is developing ALD518 in Phase 2 clinical studies in multiple cancer-related conditions, while Bristol-Myers Squibb is investigating the asset (as BMS-945429) in a Phase 2b clinical study in rheumatoid arthritis and other autoimmune indications based on a 2009 partnership. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. For more information, visit www.alderbio.com.
SOURCE Alder BioPharmaceuticals Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.